RAD327 Lu-177 Dosimetry with SPECT/CT

• Conditions: neuroendocrine tumors; C80; C17; C25.9; Malignant neoplasm, without specification of site; Malignant neoplasm of small intestine; Pancreas, unspecified

• Registration Number: DRKS00011489
• Lead Sponsor: niversitätsklinikum Magdeburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-07-19
• Study Completion: 2020-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Indication for Lutetium-177-DOTATATE therapy
- by minimum two successfully performed therapy cycles
- age > 18 years
- normal renal function
- no contraindication for the second examinations (e.g. claustrophobia, poor general condition)

Exclusion Criteria

Missing compliance to the additional examinations

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison in detection rate of focal lesions by two different SPECT/CT-systems for (1.) scintigraphy and (2.) SPECT/CT in Lutetium-177-DOTATATE therapy

Secondary Outcome Measures

Name	Time	Method
- Comparison of reader's confidence in image quality in whole body scintigraphy for both detector technologies<br>- Comparison of reader's confidence in image quality and assignment to morphologic structures for SPECT(NaJ)/CT and SPECT(CZT)/CT<br>-Comparison of uptake/nuclide accumulation in defined target regions (e.g. tumor, kidney)